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Abstract
Cardiovascular magnetic resonance (CMR) is an integral part in the diagnostic work-up of cardiac inflammatory diseases.
In this context, superparamagnetic iron oxide-based contrast agents can provide additional diagnostic information
regarding the assessment of myocardial infarction and myocarditis. After intravenous administration, these nanoparticles
are taken up by activated monocytes and macrophages, which predominantly accumulate in regions associated
with inflammation as was successfully shown in recent preclinical studies. Furthermore, first clinical studies with a
new iron oxide-complex that was clinically approved for the treatment of iron deficiency anaemia recently demonstrated
a superior diagnostic value of iron oxide nanoparticles compared to gadolinium-based compounds for imaging
of myocardial inflammation in patients with acute myocardial infarction. In this article, we outline the basic features of
superparamagnetic iron oxide-based contrast agents and review recent studies using such nanoparticles for cardiac
imaging in case of acute myocardial infarction as well as acute myocarditis. Moreover, we highlight the translational
potential of these agents and possible research applications with regard to imaging and therapy.
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Introduction
Myocardial inflammation: cause and consequences
Myocardial inflammation is associated with a broad
spectrum of pathophysiological pathways and may eventu-
ally cause both severe structural and functional impairment
of the heart muscle. In principle, myocardial inflammation
can be triggered by various stimuli – including myocardial
infections caused by pathogens such as viruses – and myo-
cardial ischemia due to coronary artery occlusion in case of
acute myocardial infarction. Such mechanisms may lead to
myocardial necrosis and initiate subsequent appropriate as
well as inadequate or excessive responses of the innate im-
mune system. Adequate activation of the immune system
may promote (amongst others) removal of dead cells and
matrix debris. By contrast, an excessive inflammatory re-
sponse may result in adverse changes of the geometry,
function and structure of heart tissue, referred to as adverse
remodelling [1, 2]. A detailed listing of immune effectors
and regulators involved in the pathophysiological states
mentioned can be found elsewhere [3, 4]. Since myocardial
inflammation may affect both primarily involved necrotic
areas as well as remote (seemingly) healthy tissue, sub-
sequent myocardial remodelling may further cause hyper-
trophy and/or dilated chambers and/or heart failure [4–6].
Therefore, the accurate assessment of an on-going
myocardial inflammation process is of paramount import-
ance regarding appropriate diagnosis of cardiac disease as
well as therapeutic decision-making and prognostic risk
stratification [3, 4]. This review focuses on the diagnostic
value of iron oxide nanoparticles for myocardial inflam-
mation imaging in case of (acute) myocardial infarction
and myocarditis.
Current (conventional) assessment of myocardial
inflammation
Cardiovascular magnetic resonance (CMR) is a well-
established technique in the diagnosis of cardiovascular
diseases. So far, non-invasive work-up of myocardial inflam-
mation with CMR is mainly based on observing alterations
in myocardial tissue composition [7]. CMR pulse sequences
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applied for diagnosing myocarditis include T2-weighted im-
aging sequences for the unspecific diagnosis of myocardial
oedema and contrast-enhanced CMR (ceCMR) for the
(again unspecific) diagnosis of necrosis and/or fibrosis
both of which may be present in myocardial infarction
or myocarditis [5]. Gadolinium contrast media washes
out rapidly in healthy myocardium whereas areas of
damaged myocardium (necrosis, fibrosis or oedema)
exhibit delayed washout kinetics. Thus, ceCMR may
depict the area of myocardial damage 10-15 min after
the injection of the contrast agent (CA) (Fig. 1) [8].
The value and accuracy of these methods and their
correlation to biopsy findings in the various phases of
human myocarditis are still under debate and more ac-
curate and more specific methods for the non-invasive
diagnosis of myocardial inflammation are desired [9, 10].
Particularly with regard to initiation of timely and ad-
equate therapy, diagnosis of myocardial inflammation
in the early phase of heart disease before the occurrence
of structural changes in the myocardium is crucial. Unfor-
tunately, T2-weighted pulse sequences which are theoret-
ically best suited to depict myocardial oedema as the first
morphological change in the sequence of events have been
unreliable in the experience of several groups studying the
diagnosis of myocarditis [11]. Hence, new CMR tools are
needed to improve both early diagnosis and specificity of
diagnosis. To enhance diagnostic accuracy, molecular and
cellular imaging methods based on iron oxide nanoparti-
cles (IONs) appear promising [12, 13].
Iron oxide nanoparticles
Nanoscaled particles with an iron oxide core and a polymer
shell have been under investigation for the last two to three
decades due to their versatile features. Probably most im-
portant, IONs exhibit superparamagnetic properties below
a certain particle size. As a result, they show a much larger
magnetic susceptibility than paramagnetic agents. However,
they lose their magnetization in the absence of an applied
magnetic field – in contrast to paramagnetic agents. An at-
tractive feature of IONs is that, depending on their size and
composition of their polymer shell, they are biocompatible
and may form stable colloidal suspensions, which are
equally important prerequisites for successful in vivo
applications (Fig. 2). After intravenous administration,
IONs disperse freely in the intravascular blood pool – until
they are eventually internalized by monocytes/macrophages
of the reticuloendothelial system (RES) [14]. Therefore,
IONs have mainly been used for blood-pool imaging or
examinations of organs associated to RES such as liver,
spleen and lymph nodes. However, in the presence of
an inflammatory disease, IONs are avidly taken up by
activated monocytes/macrophages with subsequent accu-
mulation in the affected organ/tissue [15]. In addition, free
IONs may migrate passively across leaky endothelium at
inflammatory foci and get phagocytosed by resident tissue
macrophages [12]. Thus – despite remaining predomin-
antly intravascular – IONs represent promising tracers for
inflammation. Exploiting this feature and their superior
magnetic properties, tracking and visualization of internal-
ized IONs by appropriate CMR sequences have great
potential in the assessment of inflammatory processes.
Moreover, appropriate surface modifications can func-
tionalize IONs for several applications besides imaging.
Amongst many others, their use in targeted drug delivery,
magnetofection, hyperthermia or ex vivo molecular diag-
nostics have been reported [16].
Basic design of iron oxide nanoparticles
Basic design & materials used for coating
Although IONs may differ vastly according to their desired
application (see above), they share a common structure.
Briefly, they are composed of a magnetic core and a
non-magnetic coating. The core consists of nanometre
sized, monodispersed iron oxide particles of magnetite
(Fe3O4) and/or maghemite (γ-Fe2O3). These are organized
in a crystalline pattern, which is controlled by the synthe-
sis procedure just as the core’s composition [17, 18].
Since bare iron oxide particles are insoluble in water,
tend to agglomerate and precipitate, an appropriate coating
by a polymer shell is crucial. The coating stabilizes the
Fig. 1 Cine-MR (left column) as well as T1-weighted inversion-recovery
late gadolinium enhancement (LGE, right column) images performed
in long-axis (top) and short-axis views (bottom). Damaged myocardium
exhibits delayed gadolinium washout kinetics, which in turn leads
to hyperintense areas (red arrows) visible in LGE images acquired
5-10 min after the injection of a gadolinium-based compound
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nanoparticles while its chemistry also determines the
fate of the compound since it is the polymer shell, the
host body first interacts with [18]. Throughout the lit-
erature substances such as carboxylates, phosphates,
silica, dextrans, polyethylene glycol (PEG) and chitosan
have been proposed for coating [19–24]. However, most
FDA-approved ION-based contrast agents are coated
with polysaccharide dextran or its derivatives (Table 1).
Despite further chemical aspects, dextrans are favourable
for their intrinsic affinity to iron oxide particles. In addition,
non-toxicity and good physiological tolerance have been
proven in other applications of dextrans [25].
Synthesis of iron oxide nanoparticles
Numerous synthesis pathways focusing on good reprodu-
cibility and the desired combination of core and coating
have been examined. According to Laurent et al. the sim-
plest and most efficient protocols involve co-precipitation
techniques of ferrous (Fe2+) and ferric (Fe3+) salts in an
aqueous medium with the pH adjusted [18, 26]. The for-
mulation of the final composition is achieved by applying
a stabilizing base, which is actively steered for coating [18,
27]. Techniques that are more sophisticated include e.g.
microemulsions, hydrolysis and thermolysis of precursors
or flow-injection methods as described elsewhere [28–30].
However, throughout well-known procedures, the synthe-
sis of uniform sized particles remains challenging. Thus,
IONs rather show a narrow distribution in diameter than
distinct measures [18]. Moreover, the total particle size
is additionally enlarged in solution due to solvation
[12]. According to this hydrodynamic diameter, IONs
can be class-divided as follows: Micrometre-sized iron
oxide particles are named MIONs; IONs measuring 50 nm
to 250 nm are referred to as SPIO (superparamagnetic iron
oxide particles), while those ranging from 20 nm to 50 nm
in diameter are named ultra-small SPIO (UPSIO) and even
smaller IONs (<20 nm) are declared as very-small SPIO
(VSPIO) [31].
Fig. 2 Schematic drawing of a superparamagnetic iron oxide particle (left) comprised of the magnetic core and the polymeric shell. While the
core represents the active substance of the contrast agent, the coating stabilizes the particle and can be used as a grafting platform for various
functional groups. Such iron oxide particles are taken up by activated monocytes (right) that can be visualized by Prussian blue staining.
Reproduced with permission from Boyer et al. [61] and Richards et al. [62]
Table 1 Representative examples for iron oxide-containing contrast agents
Coating Examples Size in nm Comment
Carboxymethyl- dextran Ferumoxytol (Feraheme™) 17-31 FDA approved for anaemia and in clinical use
Carboxydextran Ferucarbotran (SHU 555A, Resovist®) 45-60 FDA approved. Discontinued from clinical use in 2009.
Dextran Ferumoxtran (USPIO, AMI-227, NC100150, BMS-180549) 17-21 Discontinued after 37 clinical studies phase I-III in 2010.
Dextran Ferumoxides (Feridex™) 100 Discontinued from clinical use in 2008.
Crosslinked dextrans CLIO-Cy5.5 30-35 Experimental use
Citrate VSOP-C184 4-7 Experimental use, clinical phase I study in 2004
Representative examples for iron oxide-containing contrast agents for CMR with clinical, commercial and/or considerable experimental use adopted and modified
from Weissleder et al. [34]. Additional information and further iron oxide-based contrast agents can be seen elsewhere [40]. CLIO: cross-linked dextran iron
oxide nanoparticles
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Major properties of the core and polymer shell of
iron oxide nanoparticles
Superparamagnetism
Iron oxide nanoparticles are superparamagnetic and can
be magnetized in CMR. Superparamagnetic materials con-
sist of ferri- or ferromagnetic nanoparticles that can only
build up a single magnetic domain. For small particles such
as IONs, thermal energy is sufficient to randomly flip their
magnetic orientation [12]. Thus, in the absence of an exter-
nally applied field their net magnetization appears to be in
average zero. However, in the presence of a magnetic field
their magnetic moments align, which leads to a much
larger magnetic susceptibility than those observed for
paramagnetic agents [32]. This phenomenon is physically
described by Neel- and Brown-relaxation [33].
In the context of ceCMR, superparamagnetic IONs are
referred to as negative contrast agents. Their induced
magnetic field alters the relaxation properties in neighbour-
ing tissue, resulting in a signal void in T2/T2*-weighted
images. Thus, the performance of an ION-based contrast
agent can be quantified by the decrease in transverse
relaxation times or the increase in relaxation rate R2
(R2 = 1/T2). In general, when comparing the same particle
doses, the effect of contrast enhancement is higher for
IONs than for gadolinium-based contrast agents [12].
Uptake & blood circulation time
The main factors determining pharmacokinetics and organ
distribution of IONs are the biophysical characteristics and
their surface chemistry such as composition, density and
charge [34]. Depending on these factors, most IONs are in-
ternalized by cells of the RES and accumulate in the liver,
spleen and kidneys following intravenous administration.
SPIOs tend to accumulate in the spleen while particles
sized up to micrometres are preferentially filtered by
the liver [27, 34]. In contrast, due to their smaller size,
USPIOs show a longer blood circulation time and are
removed from the blood pool through extravasation and
renal clearance.
Cellular uptake of IONs is primarily associated with
phagocytosis. According to Weissleder et al. most dextran-
coated IONs are phagocytosed by circulating monocytes
or tissue resident macrophages [34]. Due to their large
surface-to-volume ratio, IONs tend to adsorb plasma
proteins such as opsonins which subsequently induce
phagocytosis [35]. Particularly IONs having a surface
charge that can induce bonds to phagocytes through
electrostatic interaction show increased adsorption [36].
However, cellular uptake is not only limited to phagocyt-
osis and monocytes or macrophages [34, 37]. Amongst
others, dendritic, cancer and endothelial cells also take up
IONs. Further research is needed to examine the kinetics
of ION uptake by different monocyte and macrophage
subsets as well as other cell types.
Internalization of IONs results in a decreased blood
circulation time, limiting the likelihood to reach the de-
sired/targeted tissue or organ. Several strategies to prolong
their blood half-life or to hide them towards cells of the
RES have been discussed in the literature. In principle,
particles possessing the following properties have shown a
relatively increased blood circulation time: (i) hydrophilic
coatings, (ii) hydrodynamic diameters smaller than 50 nm,
(iii) neutral or near neutral charged surface designs and
(iv) shielding groups added to the surface such as PEG
that block electrostatic or hydrophobic interactions be-
tween opsonins and particle surface [19, 25, 38].
Targeting & drug carrier
Apart from imaging purposes, IONs can also be used as
targeted carriers for drugs or small molecules. Due to
their large surface-to-volume ratio, IONs enable the in-
tegration of multiple functional groups using appropriate
surface chemistry [16]. As reviewed by Sun et al. various
studies report on the successful conjugation of targeting
agents, permeation enhancers, optical dyes or therapeutic
agents on the surface of IONs [32]. Linking between sur-
face and functional groups was achieved by electrostatic
adsorption and (amongst others) by covalent or oxidative
conjugation strategies. Appropriate bindings must be
stable in aqueous ionic solutions at physiological pH,
while ligands must not interfere with non-targeted tis-
sues and should not decrease blood circulation time
or introduce toxicological effects [18]. Again, many
strategies have been reported aiming at minimizing
detrimental effects, e.g. cross-linking IONs via their
coating material as introduced by Wunderbaldinger
and colleagues [39]. They were able to bind dextran
coated IONs by epichlorohydrin and ammonia, form-
ing complexes classified as CLIO (cross-linked iron
oxide). These compounds exhibit a flexible platform
for functionalization – but did not reach clinical ap-
proval yet [40].
Besides active targeting via functional groups, IONs
can also accumulate at targeted organs/tissues by the help
of an external magnetic field [41–43]. Exploiting the ION’s
large magnetic moment, a sufficiently high magnetic
gradient can exert drag forces from blood flow. Such an
approach allows an enhanced retention and/or accumu-
lation of IONs at the target site [44]. This approach offers
great potential for applications combining molecular
imaging and controlled drug release – sometimes re-
ferred to as theranostics [17, 44]. In comparison to
non-navigated systemic drug application, externally
navigated ION-complexes may theoretically lead to a
decrease in the required dose and in adverse side effects in
non-targeted organs while enabling monitoring of therapy
at the same time.
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Safety and toxicity
Mechanisms leading to cellular damage or impairment of
cellular viability are primarily related to surface chemistry
and functionalization of the IONs. In this context, cellular
uptake and subsequent degradation of the IONs have to
be considered. According to Singh et al. cell exposure to
IONs could theoretically induce toxic side effects such as
impaired mitochondrial function, activation of inflamma-
tory or apoptotic pathways with formation of apoptotic
bodies, generation of reactive oxygen species and even
DNA damage [36, 45]. However, in vitro studies com-
paring different metal oxide nanoparticles convincingly
showed that ION concentrations below 100 μg/ml are
safe and non-cytotoxic [46]. Moreover, human in vivo
studies examining the safety of ferumoxtran-10 or feru-
moxytol reported a convincing safety profile with only
rare occurrence of mostly mild and short lasting side
effects (such as urticaria, diarrhoea or nausea after ap-
plication) – if the respective suggestions regarding the
administration are appropriately considered [47, 48]. It
is assumed that these rare side effects are mainly associ-
ated with the endogenous degradation pathway of iron
[45, 47, 49]. However, although serious side effects are
exceedingly rare with USPIO, there have been reports
of fatal hypersensitivity responses to ferumoxytol.
Pre-clinical applications of iron oxide
nanoparticles
Myocardial infarction model
A major goal of performing ceCMR after myocardial
infarction (MI) is to differentiate injured from (remote)
healthy myocardium. In this context, Chapon et al.
evaluated dextran-coated USPIOs in a rodent model of
permanent ligation of the left coronary artery (LCA).
Concentrations of 5 and 10 mg Fe/kg were administered
once after 5 h, 24 h and 48 h of occlusion followed by
T2-weighted MR acquisitions. Subsequent image analysis
revealed higher contrast between healthy and ischemic
myocardium in series acquired at later stages. Further-
more, these authors identified a negative linear relation-
ship between contrast enhancement and the elapsed time
since induction of MI. However, doubling the concentra-
tions of IONs did not significantly increase the observed
contrast [50].
Since macrophages are primarily involved in the regula-
tion of post-MI wound healing, Sosnovik and colleagues
studied the infiltration of macrophages in the infarcted tis-
sue. Permanent ligation of the LCA was performed in
mice followed by the administration of varying concentra-
tions of a magnetofluorescent USPIO. Forty-eight hours
after ION injection, T2-weighted CMR of the myocardium
showed a negative contrast enhancement in the left ven-
tricular (LV) anterior and adjacent walls – that was not
observed in sham mice. Calculated contrast-to-noise-ratio
(CNR) between remote (healthy) myocardium and injured
LV wall segments was significantly higher for mice treated
with USPIOs. Moreover, average CNR increased with
increasing ION concentration. Since these findings were
confirmed by ex vivo immunohistochemistry (proving
co-localization of USPIO and macrophages), the authors
concluded that visualization of labelled macrophages is
feasible in vivo and allows the assessment of myocardial
injuries after infarction [51].
In contrast to the aforementioned studies, Montet-Abou
et al. investigated labelling of resting monocytes and mac-
rophages prior to occlusion-reperfusion of the left anterior
descending artery (LAD). Labelling was aimed at with
polymer-coated VSPIOs that were administered to rats
three days prior to LAD occlusion. This duration was
chosen in order to ensure total clearance of VSPIOs from
the blood pool. Following reperfusion, T2-weighted CMR
was repeated every 24 h. In doing so, hypointense areas
indicative of infarcted myocardium were only visible in
rats treated with IONs. Additional mapping of T2-values
revealed an increase in signal void (negative enhancement)
over elapsed time since reperfusion. This temporal signal
change was consistent with an increasing number of
pre-loaded monocytes and macrophages found in in-
farcted tissues by histology. Additional MR-tagging studies
showed a relationship between hypointense areas and
hypokinetic segments. In summary, the authors could
demonstrate that pre-loading and subsequent tracking
of ION-labelled macrophages is suitable to depict changes
in infarct-associated inflammatory diseases [52].
In a recent study, Protti et al. extensively investigated
the performance of VSPIOs in a murine model of ische-
mia-reperfusion [53]. The IONs were administered ac-
cording to four different experimental setups: one pre-MI
protocol that was based on the application of VSPIOs
seven days before surgery, and three post-MI protocols
that differed in the delay between reperfusion and in-
jection (24 h, 6d, 28d). The first post-MI protocol in-
cluded MR imaging and T2*-mapping 2 h, 48 h and 7d
after VSPIO application while mice in the other setups
were imaged solely after 48 h. Image analysis of the
pre-MI protocol showed no negative contrast enhance-
ment, but a decrease in functional parameters. While
the latter was related to myocardial injury, the absence
of a negative contrast enhancement was explained by
reperfusion of the infarcted territory. On the contrary,
CMR series of the first post-MI protocol showed signal
voids associated to VSPIO accumulation (Fig. 3). More-
over, Protti and colleagues found a temporal correlation
between the recovery of T2*-values and the decrease of
areas with ION-induced signal extinction. This correl-
ation was not consistent with functional and volumetric
measurements and did not apply for MR imaging six days
post-MI as performed in the second setup. Furthermore,
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no signal void was seen on CMR scans 28 days after MI
indicating the restoration of vascular integrity and/or the
endpoint of remodelling. Histological examinations per-
formed 48 h post-injection showed a high iron density
at the inner endocardial borders of infarcted areas. In
contrast, no or little iron was identified in epicardial bor-
ders. However, macrophages were identified on both sites.
Consequently, the number of macrophages did not signifi-
cantly correlate with T2*-values. Hence, the authors argued
that other cells apart from monocytes and macrophages in-
ternalized VSPIOs. Additional electron microscopy showed
an augmented VSPIO compartmentalization in macro-
phages located in endocardial areas as opposed to epi-
cardial regions. Protti and colleagues assumed that an
enhanced VSPIO-leakage into endocardial tissue might
explain their findings. Increased leakage in turn might
have originated from locally increased vessel permeability
along with a decreased tissue perfusion [53].
Myocarditis model
To the best of our knowledge, there is only one pre-
clinical animal study published so far that addresses
ION-administration and CMR of inflammatory pro-
cesses associated with myocarditis: In 2012, Moon and
colleagues presented the results of their comprehensive
rodent study, examining the feasibility to detect and dis-
criminate different grades of experimental autoimmune
myocarditis (EAM) by the help of SPIOs. They used IONs
covered by a fluorophore-incorporated silica coating that
were additionally conjugated with PEG polymer chains.
Experimental setups involved injection of 10 mg Fe/kg on
day 21 after induction of EAM or 24 h before CMR, re-
spectively. Histological examinations comprising different
staining and microscopy techniques were performed after
imaging [54]. First, ex vivo imaging of inflammatory
cellular infiltrates was performed in rats at day 21 after in-
duction of EAM and 24 h after SPIO-injection. Markedly
Fig. 3 Comparison of explanted hearts from mice after induced myocardial infarction (top row) and after sham procedure (bottom row). Images
a and d show myocardium stained with Evans blue indicating areas with enhanced permeability in the area of myocardial infarction (a, arrows).
The corresponding sections display damaged tissue only for infarcted hearts (b vs. e) and corresponding signal void in T2-weighted MR images
after infusion of VSPIO (c vs. f). Reproduced with permission from Protti et al. [53]
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enlarged hearts with dilated ventricles, thickened myo-
cardium and scattered inflammatory foci of varying sizes
were observed. Moreover, histological analysis revealed
a dense accumulation of macrophages in pathologically
altered areas with SPIOs compartmentalized in lyso-
somes [54].
To evaluate in vivo assessment of EAM using SPIO-
based ceCMR, Moon and collaborators determined the
CNR of the LV septum between pre- and post-SPIO
images. T2-weighted images acquired 30 min after in-
jection of SPIOs showed homogenous negative contrast
enhancement in ventricle walls of both EAM and control
rats indicating SPIO accumulation. Consequently, CNR
was significantly decreased. While contrast normalized
after 24 h in the control group, areas of negative contrast
enhancement persisted in EAM rats. In accordance to
histological findings, the authors assumed that IONs were
present in the vasculature after the injection in both
groups, but were washed-out from site afterwards in
control rats. Further, they presume that inflammatory
cells including macrophages infiltrated affected tissue
and phagocytosed SPIOs preventing their washout in
rodents infected with EAM [54].
To evaluate the diagnostic yield of SPIO-based ceCMR
regarding discrimination of histologically defined grades
of myocardial inflammation, CMR was performed at differ-
ent days after induction of EAM. A linear relationship was
found between changes in CNR and stained areas of both
inflammation and macrophage counts for all grades. How-
ever, the authors did not observe a significant difference in
CNR between moderate and severe forms of EAM [54].
In another experimental setup, the distinctiveness of
SPIO-based ceCMR was compared to T2-weighted images
as well as to early (EGE) and late-gadolinium-enhanced
(LGE) CMR. All images were acquired sequentially in-
cluding SPIO-based ceCMR in the same rats. In doing
so, gadolinium-based ceCMR showed large areas of inflam-
mation, but no small foci that were visible in SPIO-based
ceCMR (Fig. 4). Since these rather small inflammatory areas
were confirmed by staining, the authors deduced a superior
Fig. 4 Comparison between SPIO-CMR and LGE-CMR. T1-weighted LGE-CMR before (a) and after (b) gadolinium injection, and T2*-weighted
SPIO-CMR before (d) and after (e) SPIO injection in the same EAM rats are compared. Whereas weakly enhanced areas (b, white arrowheads) are
visualized in the left ventricular wall in the LGE-CMR, the positively enhanced area becomes negative contrasted (e, white arrowheads) in SPIO-CMR.
Magneto-fluorescent nanoparticle CMR provides more specific identification of inflammatory lesions (e, yellow arrows) than LGE-CMR and
more pronounced changes in CNR (c and f). The negative contrast regions in the SPIO-CMR are in good agreement with inflamed areas in
H&E images (g), macrophage infiltrations in IHC images (h), and SPIO-fluorescence spots in FM (i). CNR: contrast-to-noise ratio; H&E: haematoxylin and
eosin; IHC: immunohistochemistry; FM: fluorescence microscopy. Reproduced with permission from Moon et al. [54]
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diagnostic accuracy for IONs. This observation is in ac-
cordance with the patchy pattern of necrosis and viable
myocytes in myocarditis that makes appropriate detection
by a gadolinium-based contrast-approach challenging [54].
Additional studies addressed the issue of assessing the
evolution/disease course of EAM. IONs were administered
in the same rats at day 15 and 20, respectively, after
the induction of EAM. At day 16, SPIO-based ceCMR
showed several inflammatory spots with significantly
decreased pre- vs. post-SPIO CNR. In comparison, dif-
ferent contrast patterns and areas that tended to have
an even lower CNR were observed at day 21. Further-
more, repeated CMR studies of EAM-rats 24 h, 72 h
and 120 h after SPIO application at day 18 showed no
migration of labelled macrophages into the neighbour-
ing myocardium [54].
Clinical applications of iron oxide nanoparticles
for myocardial inflammation imaging
Although many preclinical studies in different animal
models and with different IONs rather consistently dem-
onstrated that non-invasive visualization of myocardial in-
flammation with CMR is possible and based on in vivo
and/or ex vivo labelling of monocytes/macrophages (Table 2),
the number of clinical studies aiming at ION-based de-
piction of myocardial inflammation is quite limited. So
far, clinical studies with IONs were only performed in
patients with acute myocardial infarction and no clinical
data are available in patients with myocarditis or other
inflammatory diseases of the heart that are not caused
by coronary artery disease.
The first clinical trial in patients with acute myocardial
infarction (entitled NIMINI-1) was performed by our
group using ferucarbotran, a SPIO approved at that time
as Resovist® for a non-cardiac indication [55]. Twenty
patients with either an acute ST-elevation MI (STEMI)
or non-ST-elevation MI (NSTEMI) were included to
this pilot-study. After coronary angiography, a first baseline
CMR study was performed within seven days after onset of
cardiac symptoms and a second CMR study at different
time points (10 min to 48 h) after intravenous single-dose
injection of ferucarbotran. Following ferucarbotran admin-
istration, the area of myocardial hypoenhancement in
T2-/T2*-weighted images (suggestive of either SPIO accu-
mulation and/or intramyocardial haemorrhage) did not
exceed the area of conventional LGE and no statistical
significant difference were seen when pre-SPIO images
were compared to post-SPIO ones. Hence, T2-/T2*-weighted
CMR imaging using the approved dose of ferucarbotran
(39 mg Fe/patient) did not result in an improved visual-
isation of inflamed/infarcted myocardium compared to
conventional gadolinium-based necrosis/fibrosis imaging
in this trial.
However, the reasons for this disappointing result were
quite obvious: There is a linear relationship between
the applied dose of U/SPIO and the degree of induced
hypoenhancement in T2-/T2*-weighted images. The min-
imal concentration successfully used in animal models was
2-3 mg Fe/kg. Unfortunately, the approved dose of Reso-
vist® (for patients with suspected liver disease) was one sin-
gle injection of 1.4 ml Resovist® - corresponding to a dose
of 39 mg Fe per patient. Due to medicolegal reasons, our
group was not allowed to use a different dose at that time.
Thus, the maximal Fe concentration after administration of
Resovist® (e.g. in a 60 kg patient) was only 0.65 mg Fe/kg.
Moreover, Resovist®’s blood half-life was possibly too short
(<15 min) for efficient uptake in macrophages and accumu-
lation in the infarcted myocardium.
Recently, the group of Newby and co-workers from
Edinburgh and our group independently (and at the
same time) performed new clinical trials in patients with
acute STEMI using for the first time ferumoxytol, an
USPIO that was approved by the FDA for treatment of
anaemia in patients with renal disease. The group from
Edinburgh studied 10 patients (and 6 controls) and used
a ferumoxytol concentration of 4 mg Fe/kg. CMR scans
comprising T2*-weighted sequences were performed on
a 3-T scanner within five days of admission at baseline,
24 h and 48 h and R2* values were calculated for specific
regions of interest. In regions with infarcted myocardium,
Table 2 Overview of cited pre-clinical animal studies
Object of study Field-strength
B0 in T











7.0 42 1, 5, 10 50 Dextran 0.8 R1 = 1.2, R2 = 24; (7 T)
Sosnovik et al.
2007 [51],




et al. 2009 [52],
1.5 44 10 15 Polymer 6
Protti et al.
2014 [53],
7.0 73 15 7 Citrate 2 R1 = 30, R2 = 39; (0,47 T)
Myocarditis Moon et al.
2012 [54],
4.7 90 10 85 Silica 2.8 R2 = 130; (4,7 T)
Overview of cited pre-clinical animal studies, including particle doses used and physical properties - partially adapted from MICAD [40]. * half-life in rodent blood
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the R2* value increased from 41.0 ± 12.0 s(−1) at baseline
to 155 ± 45.0 s(−1) (p < 0.001) at 24 h and to 124 ±
35.0 s(−1) (p < 0.05) at 48 h. Interestingly, a similar,
however, lower change in R2* was documented in the
remote (non-infarcted) myocardium while no change at
all was detected in the skeletal muscle in this study [56].
Our clinical phase-III trial with ferumoxytol (entitled
NIMINI-2) comprised 14 patients with acute STEMI.
After a first baseline CMR study (pre-USPIO) on a 1.5-T
scanner, a follow-up CMR study (post-USPIO) was per-
formed 48 h after administration of ferumoxytol. In this
trial, the approved dose of ferumoxytol (containing 510 mg
Fe in 17 ml solution) was used - resulting in a concen-
tration of e.g. 8.5 mg Fe/kg in a 60 kg subject - while the
median dose of iron was 5.4 mg Fe/kg in the NIMINI-2
study. The median extent of T2-weighted hypoenhance-
ment in the region of myocardial infarction - which was
not present in baseline studies in any patient (!) - was 19%
(IQR 14-22%) (Fig. 5). Similar to the aforementioned
study, a substantial drop in absolute T2*-values (corre-
sponding to an increase in R2*-values) was observed
not only in the infarct core and peri-infarct zone, but
also in the remote (healthy) myocardium. In addition,
there was only a minor change in the T2*-value of the
skeletal muscle. Additional ex vivo analyses showed that a
substantial ferumoxytol uptake was detected only in cul-
tured macrophages, but not in peripheral blood monocytes
from study patients. Taken together, we could demonstrate
in humans that an USPIO-based approach allowed de-
tailed characterization of infarct pathology by causing
hypoenhancement (in T2-weighted images) and signal
void (in T2*-mapping images), mainly by detecting infil-
trating macrophages and most likely by altered tissue
partitioning of USPIOs in different layers of the infarcted
myocardium [57].
Compared to ferucarbotran (an SPIO that was used in
the NIMINI-1 study), ferumoxytol is an USPIO with a
mean diameter of only ~30 nm, a neutral surface charge,
a magnetic relaxivity of r1 = 15 mmol/L/s and r2 =
89 mmol/L/s (at 1.5 T) and a blood half-life of ~15 h.
Such a long blood half-life that is due to its small size
and neutral surface charge is a prerequisite for accu-
mulation of such particles (during continuous blood
circulation) in the inflamed/infarcted myocardium. Al-
though ferumoxytol is not approved as an CMR contrast
agent so far, the specific magnetic relaxivity properties
of ferumoxytol do allow both T1-weighted as well as
T2-/T2*-weighted MR imaging – as was shown in the
NIMINI-2 study. Noteworthy, ferumoxytol was devel-
oped by AMAG Pharmaceuticals, Inc., in the USA and
was first approved as FerahemeTM for iron replacement
therapy in patients with anaemia due to chronic renal
failure in June 2009 by the FDA. Subsequently, in June
2012 the company Takeda received European marketing
Fig. 5 Exemplary cardiovascular magnetic resonance images in the long-axis view of a study patient with a septal myocardial infarction who
underwent pre-Feraheme™ (FH) (baseline) and post-Feraheme™ (after 6, 24, 48 h) cardiovascular magnetic resonance imaging studies, respectively.
The first line shows cine-cardiovascular magnetic resonance images at different time points with proof of hyperenhancement in the septal wall at
6–48 h post-Feraheme™ (red arrows). The second line shows T2-weighted short-tau inversion recovery-spin echo images at different time points
with proof of hypoenhancement in the septal wall at 6–48 h post-Feraheme™ (red arrows). Reproduced with permission from Yilmaz et al. [57]
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authorization for Rienso® (i.e. 510 mg ferumoxytol) and
started to launch Rienso® across Europe. Unfortunately,
Rienso® is no longer marketed in Europe due to commer-
cial reasons. Moreover, since ferumoxytol is not renally
eliminated, it can also be safely administered to patients
with severe renal dysfunction – in contrast to gadolinium-
based compounds.
Current challenges and future promises of iron
oxide nanoparticles for myocardial inflammation
imaging
From a clinical point-of-view, the opportunity to image/
visualize infiltrating macrophages in the inflamed myocar-
dium will be of potential diagnostic as well as therapeutic
value since the extent and degree of myocardial disease
might be monitored more accurately and therapeutic
success might be assessed more appropriately. Moreover,
USPIOs such as ferumoxytol may help to differentiate
acute myocardial inflammation from rather chronic myo-
cardial disease (such as myocardial fibrosis) – which is not
possible with current conventional gadolinium-based
approaches. In this context, future applications of USPIO
may also comprise other cardiac diseases that are char-
acterised by myocardial inflammation such as cardiac
transplant rejection or cardiac sarcoidosis.
Recently, two distinct phases in the process of infarct
healing were described [58]: a first inflammatory phase
(until day ~4 following acute MI) that is characterized by
the accumulation of pro-inflammatory monocytes (CD16−)
that primarily remove necrotic cells and debris, and a sec-
ond resolution phase (following day ~4 after acute MI)
in which reparative monocytes (CD16+) predominate
and orchestrate myocardial tissue repair. In addition,
recent preclinical studies suggest that a misbalance be-
tween these two phases (e.g. an excessive accumulation
of inflammatory monocytes during the first phase) may
have adverse effects on infarct healing [59]. Therefore,
future imaging studies need to consider such complex
and sophisticated mechanisms and aim at detecting spe-
cific subsets of monocytes/macrophages in the human
myocardium in order to allow an improved understanding
of monocyte trafficking in the inflamed heart. Obviously,
USPIO-based imaging of monocytes/macrophages that
was performed in clinical studies so far did not (and still
do not) allow such a subtle differentiation of monocyte/
macrophage subsets.
Moreover, it has to be expected that monocyte/macro-
phage trafficking in case of non-ischemic inflammatory
diseases such as myocarditis will show different patterns
of monocyte/macrophage activation with different cell
subsets being involved. Hence, the affinity of IONs to
monocytes/macrophages involved in acute (human)
myocarditis might be different compared to those ones
orchestrating inflammation in case of myocardial infarction.
Future clinical studies with comprehensive myocardial tis-
sue as well as blood analyses will hopefully allow evaluating
such sophisticated differences.
Although (passive) uptake of IONs by infiltrating mono-
cytes/macrophages seems to be the major mechanism
leading to myocardial signal void on T2-/T2*-weighted
CMR images, the pre-clinical data of Protti et al. [53]
as well as the clinical data from the NIMINI-2 trial [57]
suggest that altered tissue partitioning of USPIOs in
different layers of the infarcted myocardium – independent
of the amount of macrophages (!) - needs to be considered
carefully. Whether the degree of microvascular obstruction
and/or the presence and frequency of other cell types (apart
from monocytes and macrophages) constitutes another
reason for this observation needs to be evaluated in fu-
ture studies.
Finally, the versatile coating properties of USPIOs in
addition to the possibility to navigate such particles to the
targeted organ/tissue by using external permanent magnets,
make these particles highly suitable as versatile drug-
carriers for targeted therapy. Since stem cell transplantation
is a promising strategy for therapy of acute myocardial
infarction and of CAD-driven heart failure, USPIO may
also be used to label, target and subsequently visualize such
cells in vivo using CMR. Recently, Cheng et al. [60] per-
formed a very elegant preclinical study and applied targeted
nanomedicine to achieve the following effects at the same
time: a) in vivo cell-mediated repair of infarcted myocardial
tissue, b) non-invasive CMR-based therapy monitoring
using USPIO and c) targeted accumulation of bone
marrow-derived stem cells in the infarcted myocardium,
however, without cellular transplantation. These goals were
achieved by linking USPIO with two types of antibodies:
An anti-CD45 antibody was used to target exogenous bone
marrow-derived stem cells (expressing CD45) and an anti-
MLC antibody to target injured cardiomyocytes (expressing
MLC). After infusion of such USPIO (linked with two dif-
ferent antibodies), accumulation of bone marrow-derived
stem cells in the infarcted area was achieved by an external
magnet (1.3-T) that was positioned above the left thoracic
region during USPIO infusion and continuously for 10 min
after infusion. These authors’ results indicate that scar
formation may be reduced and left ventricular function
improved by using such an elegant approach. Hence, IONs
such as USPIO could have far-reaching consequences for
future developments regarding molecular diagnostics as
well as targeted therapy.
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